Autosomal Dominant Polycystic Kidney Disease Overview

Save information for later
Sign Up

Learn About Autosomal Dominant Polycystic Kidney Disease

What is the definition of Autosomal Dominant Polycystic Kidney Disease?
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. ADPKD is a progressive disease and symptoms tend to get worse over time. The most common symptoms are kidney cysts, pain in the back and the sides and headaches. Other symptoms include liver and pancreatic cysts, urinary tract infections, abnormal heart valves, high blood pressure, kidney stones, and brain aneurysms. ADPKD is most often caused by changes in the PKD1 and PKD2 genes, and less often by changes in the GANAB and DNAJB11 genes. It is inherited in a dominant pattern. ADPKD is the most common inherited disorder of the kidneys.
What are the alternative names for Autosomal Dominant Polycystic Kidney Disease?
  • Autosomal dominant polycystic kidney disease
  • ADPKD
  • Polycystic kidney disease, adult type
Who are the top Autosomal Dominant Polycystic Kidney Disease Local Doctors?
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Neera K. Dahl
Nephrology
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Neera K. Dahl
Nephrology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neera Dahl is a Nephrologist in Rochester, Minnesota. Dr. Dahl is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. Her top areas of expertise are Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Disease, Kidney Stones, and Kidney Transplant. Dr. Dahl is currently accepting new patients.

Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Vicente E. Torres
Nephrology
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Vicente E. Torres
Nephrology

Mayo Clinic

200 1st St Sw, 
Rochester, MN 
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vicente Torres is a Nephrologist in Rochester, Minnesota. Dr. Torres is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. His top areas of expertise are Autosomal Dominant Polycystic Kidney Disease, Polycystic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, Kidney Transplant, and Nephrectomy. Dr. Torres is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Ronald D. Perrone
Nephrology
Elite in Autosomal Dominant Polycystic Kidney Disease
Dr. Ronald D. Perrone
Nephrology
750 Washington St, Nemc Box 836, 
Boston, MA 
617-636-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ronald Perrone is a Nephrologist in Boston, Massachusetts. Dr. Perrone is rated as an Elite provider by MediFind in the treatment of Autosomal Dominant Polycystic Kidney Disease. His top areas of expertise are Autosomal Dominant Polycystic Kidney Disease, Polycystic Kidney Disease, Chronic Kidney Disease, Autosomal Recessive Polycystic Kidney Disease, and Kidney Transplant. Dr. Perrone is currently accepting new patients.

View All Doctors
What are the latest Autosomal Dominant Polycystic Kidney Disease Clinical Trials?
NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease
NOX4, Mitochondria and Related Biomarkers in Autosomal Dominant Polycystic Kidney Disease
Enrollment Status: Recruiting
Publish Date: October 15, 2025

Summary: To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
Enrollment Status: Recruiting
Publish Date: September 30, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center